Adenocarcinoma and Pulmonary Tumor Thrombotic Microangiopathy.

By Emin Gayibov
Amin H. Karim MD

A Rapid Review of Adenocarcinoma and Pulmonary Tumor Thrombotic Microangiopathy: A Deadly Duo

Emin Gayibov • Amin H. Karim

Published: January 03, 2025 DOI: 10.7759/cureus.76842 

Peer-Reviewed

Cite this article as: Gayibov E, Karim A H (January 03, 2025) A Rapid Review of Adenocarcinoma and Pulmonary Tumor Thrombotic Microangiopathy: A Deadly Duo. Cureus 17(1): e76842. doi:10.7759/cureus.76842

Abstract

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare paraneoplastic syndrome associated with various adenocarcinomas, most commonly gastric adenocarcinoma. This condition can progressively worsen pulmonary arterial hypertension, leading to acute or subacute pulmonary heart failure and respiratory insufficiency. This paper examines the pathogenesis, clinical presentation, diagnosis, treatment, and prognosis of PTTM. Given PTTM’s poor prognosis, we emphasize treatment strategies. PTTM in adenocarcinoma patients can mimic other pulmonary diseases, causing diagnostic delays. Current PTTM treatment strategies primarily focus on managing the underlying malignancy and addressing thrombotic complications. Anti-angiogenic therapy with bevacizumab and the platelet-derived growth factor receptor antagonist imatinib have shown promise in multiple cases. Further research is needed to develop more effective and targeted therapies for this challenging condition. The precise mechanisms underlying this association remain to be fully elucidated.

Introduction & Background

Paraneoplastic syndromes constitute a diverse group of clinical disorders associated with malignant diseases that can significantly impact patient morbidity and mortality. They are not directly attributable to the physical effects of the primary or metastatic tumor [1]. In these syndromes, malignant cells do not directly cause symptoms related to metastasis; rather, they induce the generation of autoantibodies, cytokines, hormones, or peptides that exert effects on multiple organ systems [2]. It is estimated that paraneoplastic syndromes affect up to 8% of patients with cancer [3]. Table 1 provides a concise overview of commonly encountered paraneoplastic syndromes [4-23].

Organ system	Paraneoplastic syndrome	Most associated cancer type	Clinical signs
Neurological	Paraneoplastic encephalitis	SCLC, testicular cancer	Cognitive dysfunction, seizures, personality changes, hallucinations, autonomic dysfunction
	Subacute cerebellar degeneration	Breast, ovarian, SCLC, Hodgkin lymphoma	Ataxia, dysarthria, dizziness, diplopia, nausea, vomiting
	Opsoclonus-myoclonus syndrome	Neuroblastoma (children), SCLC (adults)	Rapid eye movements, body jerks, ataxia, hypotonia
	Myasthenia gravis	Thymoma	Muscle weakness, ptosis, diplopia, diaphragmatic weakness
	Lambert-Eaton myasthenic syndrome	SCLC	Proximal muscle weakness, autonomic dysfunction, diminished reflexes
	Autonomic neuropathy	SCLC, thymoma	Dry mouth, altered pupillary reflexes, orthostatic hypotension, GI dysfunction
	Subacute sensory neuropathy	SCLC	Paresthesia, neuropathic pain, diminished sensation
Endocrine	Cushing syndrome	SCLC, pancreatic cancer	Hypertension, centripetal obesity, hypokalemia, edema
	SIADH	SCLC	Hyponatremia, lethargy, confusion, seizures
	Hypercalcemia	Lung, renal cell, multiple myeloma	Lethargy, nausea, bradycardia, short QT interval on ECG
	Non-islet tumor hypoglycemia	Fibrosarcoma, hepatocellular carcinoma	Hypoglycemia, confusion, seizures
	Carcinoid syndrome	Bronchial carcinoid, pancreatic carcinoma	Flushing, diarrhea, bronchospasm
	Hyperaldosteronism	Adrenal adenoma, non-Hodgkin lymphoma	Hypertension, hypokalemia
Rheumatological	Paraneoplastic polyarthritis	Various malignancies	Migratory, asymmetric arthritis
	Polymyalgia rheumatica	Myelodysplastic syndrome	Pain and stiffness in shoulders, neck, and hips
	Hypertrophic osteoarthropathy	Lung cancer	Digital clubbing, joint swelling, periostitis
	Multicentric reticulohistiocytosis	Various malignancies	Papules, nodules, destructive polyarthritis
Hematological	Polycythemia	Renal cell carcinoma, cerebellar hemangioma	Increased hemoglobin, pallor, fatigue
	Trousseau syndrome (migratory thrombophlebitis)	Pancreatic, Bronchogenic carcinoma	Painful migratory thrombophlebitis
Dermatological	Acanthosis nigricans	Gastric adenocarcinoma	Hyperpigmented, velvety plaques in axilla, neck
	Paraneoplastic pemphigus	B-cell lymphoproliferative disorders	Blisters, mucosal erosions
	Sweet syndrome	Hematological malignancies	Painful, erythematous plaques with fever
	Dermatomyositis	Ovarian, lung, pancreatic cancer	Heliotrope rash, Gottron papules, proximal muscle weakness
Renal	Nephrotic syndrome	Various tumors	Proteinuria, edema, fluid overload
	Electrolyte imbalances	SCLC, thymoma	Hyponatremia, hyperphosphatemia, acid-base disturbances
Pulmonary	Pulmonary tumor thrombotic microangiopathy	Various adenocarcinomas	Microvascular thrombosis, endothelial injury, and severe pulmonary arterial hypertension
	Lymphangitic carcinomatosis	Various adenocarcinomas	Progressive dyspnea, cough, and hypoxemia
	Pulmonary alveolar proteinosis	Leukemia, lymphoma	Progressive respiratory insufficiency

Table 1: A concise overview of paraneoplastic syndromes including pulmonary tumor thrombotic microangiopathy

Source: [4-23]

SCLC, small cell lung carcinoma; SIADH, syndrome of inappropriate antidiuretic hormone secretion

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and often underrecognized paraneoplastic syndrome associated with various adenocarcinomas, often linked to gastric adenocarcinoma [24]. Although less frequently observed, breast, lung, and urothelial malignancies have also been linked to PTTM [25]. Post-mortem examinations of carcinoma patients indicate a PTTM prevalence ranging from 1.4% to 3.3% [24,26]. This condition can lead to a progressive deterioration of pulmonary arterial hypertension (PAH), culminating in acute or subacute pulmonary heart failure and respiratory insufficiency. Hence, early recognition and treatment are crucial to prevent irreversible lung damage and complications. First described by von Herbay et al. in 1990 [26], PTTM is characterized by the presence of numerous tumor emboli within the pulmonary microvasculature, leading to microvascular thrombosis and endothelial injury. Later studies have highlighted the critical role of tumor-derived factors in driving hypercoagulability and angiogenesis, as explained in the pathogenesis section.

In this paper, we will examine the pathogenesis, clinical presentation, diagnosis, treatment, and prognosis of PTTM in patients with adenocarcinoma of various origins. Given the poor prognosis associated with PTTM, we will place particular emphasis on treatment strategies. We will discuss the approaches taken in different cases in recent years to inform current best practices, including their limitations and potential avenues for improvement. This rapid review will delve into the current understanding of this rare paraneoplastic syndrome and its potential clinical implications. By reviewing the available literature, we aim to shed light on the pathophysiology, clinical manifestations, diagnostic challenges, and therapeutic options for PTTM.

Review

Methodology

All the studies referred for this rapid review have been searched via the National Library of Medicine (NIH), PubMed, with the free-text keywords “pulmonary tumor thrombotic microangiopathy (PTTM)”, “PTTM AND adenocarcinoma”, “pathogenesis AND PTTM”, “clinical presentation AND PTTM”, “diagnosis AND PTTM”, “treatment AND PTTM”, and “prognosis AND PTTM”. A visual tool Connected Papers [27] and reference manager software Mendeley [28] served for proper citation and access to the studies regarding the abovementioned aspects of PTTM. For this rapid review, we did not specify the time range of studies referred due to insufficiency in number. Our inclusion criteria comprised type I tumor embolism, which is the “classic” or “true” type originating from a distant primary tumor via hematologic seeding with no invasion into vessel walls. Among type I tumor embolism studies, we included ones that specifically focused on the PTTM, either antemortem or postmortem, as a confirmed diagnosis. We disregarded the studies involving type II tumor embolism, which results from a tumor growing into the pulmonary arteries with invasion into vessel walls. The search strategy is summarized in Table 2.

Items	Specification
Date of search	1 October 2024 to 17 November 2024
Databases and other sources searched	National Library of Medicine, PubMed
Search terms used	“pulmonary tumor thrombotic microangiopathy (PTTM)”, “PTTM AND adenocarcinoma”, “pathogenesis AND PTTM”, “clinical presentation AND PTTM”, “diagnosis AND PTTM”, “treatment AND PTTM”, and “prognosis AND PTTM”
Timeframe	No specific timeframe
Inclusion and exclusion criteria	Case reports and reviews were included if they specifically focused on PTTM as type I tumor embolism, the “classic” or “true” type originating from a distant primary tumor via hematologic seeding without vessel wall invasion. Studies involving type II tumor embolism, resulting from a tumor growing into the pulmonary arteries with vessel wall invasion, and mixed embolism were excluded
Selection process	A total of 164 studies were initially identified, of which 55 were ultimately included Author E.G. conducted the literature selection. A.K. supervised the search strategy.
Any additional considerations	Connected Papers [27] and Mendeley [28] served for proper citation and access to the studies

Table 2: Summary of the search strategy for this rapid review

Pathogenesis of pulmonary tumor thrombotic microangiopathy

Associated with mucin-secreting adenocarcinomas, PTTM is a specific type of pulmonary tumor embolism. It is classified within type I tumor embolism, the “classic” or “true” type originating from a distant primary tumor via hematologic seeding without vessel wall invasion [29,30]. In contrast, type II tumor embolism arises from a tumor growing into the pulmonary arteries with invasion into vessel walls [31]. In terms of histopathology, PTTM is characterized by fibrocellular intimal proliferation of small and medium pulmonary arteries and arterioles with the presence of tumor emboli [26,32]. This distinctive feature can be observed using various histological staining techniques, such as Verhoeff-Van Gieson and alpha-smooth muscle actin immunohistochemistry [33,34]. Fibrocellular intimal proliferation involves the growth of cells, primarily smooth muscle cells and fibroblasts, and extracellular matrix within the intima of small pulmonary arteries and arterioles. This leads to narrowing of the vessel lumen. Reactive fibrointimal thickening and occlusion were also revealed in the pulmonary lymphatic vessels and veins in a particular PTTM case [35]. It has also been reported that PTTM is frequently associated with lymphangiosis carcinomatosa, a serious condition that occurs when cancer cells spread to the lymph vessels, causing inflammation and blockage and becoming a predisposing factor to PTTM [26,36]. In PTTM, multiple microscopic tumor cells become stuck to the inner lining of small pulmonary blood vessels. This triggers an inflammatory response, causing the vessel walls to thicken and narrow. Additionally, blood clots form within these vessels, further restricting blood flow. As a result, the lung’s blood vessel network becomes severely compromised, leading to PAH [37,38].

In PTTM, tumor cells not only physically obstruct blood vessels but also release tissue factor (TF), which activates the blood clotting system. They also release inflammatory mediators that promote inflammation and growth factors that stimulate the growth of vessel tissue. This excessive growth can lead to a thickening of the vessel walls, narrowing the blood passage and further hindering the blood flow. Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) produced by tumor cells, and versican (VCAN), an extracellular matrix proteoglycan, are considered to be the important factors involved in pulmonary vascular remodeling seen in PTTM [39-41]. Growth factors, particularly transforming growth factor-β (TGF-β), stimulate the expression of VCAN. VCAN binds to growth factors and other extracellular matrix components, creating a local reservoir for these factors [42]. Furthermore, VCAN-hyaluronan aggregates occur in various human lung diseases, including PAH, and provide a permissive environment for arterial smooth muscle growth [41]. These aggregates can be visualized using specific staining techniques with primary antibodies targeting VCAN and hyaluronan-binding protein [43]. Tumor necrosis factor-α, another cytokine released by tumor cells, induces changes in endothelial cell functions, such as upregulation of TF, contributing to the activation of blood clotting system [44].

As previously stated, PTTM is strongly associated with mucin-secreting adenocarcinomas. Mucin production by these tumors likely contributes to the development of PTTM through several mechanisms. Mucinous material can encapsulate tumor cells, forming emboli that travel to the lungs and cause vascular obstruction. Additionally, mucin can stimulate inflammation and damage the vessel walls, further promoting thrombosis. The pro-inflammatory nature of mucin can activate coagulation pathways, leading to thrombus formation [45,46]. While the exact mechanisms are still under investigation, it is clear that mucin plays a significant role in the pathogenesis of this complex disease. Furthermore, circulating tumor-derived, TF-positive microparticles are strongly associated with the activation of blood coagulation, another potential mechanism contributing to the pathogenesis of PTTM that warrants further investigation [47]. Tumor cells express TF and spontaneously release TF-positive microparticles into the bloodstream. Microparticles are small membrane vesicles that exhibit high procoagulant activity. It has been proposed that these circulating tumor-derived, TF-positive microparticles may contribute to the increased rates of thrombosis, including PTTM, as observed in cancer patients [47]. Further contribution to the prothrombotic state can be via a decrease in ADAMTS13 activity. ADAMTS13 is an enzyme responsible for cleaving von Willebrand factor (VWF), a protein involved in blood clotting [48]. Reduced ADAMTS13 leads to an accumulation of large, multimeric forms of VWF. These large VWF multimers are more potent at binding platelets and promoting their aggregation [48,49]. This increased platelet aggregation significantly increases the risk of blood clot formation, contributing to the development of venous thromboembolism and other thrombotic complications in cancer patients, possibly including PTTM.

The interaction between the tumor emboli and endothelial cells via multiple mediators eventually results in the consumption of coagulation factors and platelets, consistent with commonly found laboratory findings, including thrombocytopenia, and disseminated intravascular coagulation (DIC) [25]. Subsequent impaired fibrinolysis in PTTM disrupts the body’s ability to dissolve blood clots in the lungs. This occurs due to an imbalance between clot formation and breakdown, with factors such as increased levels of plasminogen activator inhibitor-1 and decreased levels of tissue plasminogen activator playing significant roles [50]. The resulting persistent blood clots contribute to the development of PAH, right ventricular failure, and other serious complications. The pathogenesis of PTTM is summarized in Figure 1. While growth factors such as PDGF, VEGF, and TGF-β are implicated, the precise molecular pathways driving tumor cell proliferation and invasion in PTTM remain unclear. The mechanisms by which tumor cells arrest in the pulmonary circulation and the role of specific inflammatory mediators in this process need further investigation. The complex interplay of these factors highlights the intricate mechanisms underlying PTTM and emphasizes the need for further research to unravel the precise molecular pathways involved.

Figure 1: Summary of the pathogenesis of pulmonary tumor thrombotic microangiopathy

Clinical presentation and diagnosis of pulmonary tumor thrombotic microangiopathy

Multiple case reports show that the most common symptoms of PTTM include cough, sputum production, shortness of breath, inability to lie down at night, chest tightness, chest pain, hemoptysis, fever, malaise, and wasting. Additionally, fatigue, weight loss, fluid buildup in the legs and ankles, and bluish discoloration of the skin are also reported systemic symptoms [51-54]. In clinical settings, PTTM is primarily a preliminary diagnosis made through a combination of the patient’s medical history, physical examination, echocardiographic and CT imaging, and laboratory tests in patients with cancer. The recognition of PTTM in cancer patients is crucial for several reasons. Firstly, PTTM can significantly worsen the prognosis of cancer patients by accelerating disease progression and increasing the risk of thromboembolic events. Secondly, early diagnosis and appropriate management of PTTM can help alleviate respiratory symptoms and improve quality of life. A diagnosis of PTTM requires a high index of suspicion, especially in patients with sudden onset dyspnea but no radiological findings pointing to pulmonary embolism [55]. Clinicians should be vigilant for PTTM in patients with cancers such as breast, lung, and ovarian, especially those undergoing chemotherapy or with advanced disease. Key symptoms include sudden shortness of breath, chest pain, cough, and hemoptysis [51-54]. Thorough evaluation, including blood tests, chest imaging, and consideration of other diagnoses such as pulmonary embolism and pneumonia, is essential. The challenge in the diagnosis of PTTM can be explained by the low rate of antemortem versus a high rate of postmortem diagnosis, as nearly 80% of identified cases were diagnosed by autopsy [25]. A study by Bak et al. highlights the challenge of diagnosing PTTM. Over 10 years at a tertiary center, they collected 28 cases suspected of PTTM, with only one confirmed histologically [56]. This underrecognition can be further attributed to its nonspecific clinical presentation, rapid disease progression, and the overall rarity of the condition, which often delays consideration in the differential diagnosis.

The clinical presentation of PAH, right ventricular failure, and abnormal laboratory studies including elevation in D-dimer and prothrombin time, the presence of anemia and thrombocytopenia, and DIC should prompt consideration of PTTM [25,57]. Schistocytes may be present in the peripheral blood smear in PTTM, as red blood cells can be sheared by the thickened intima. However, their presence alone is not diagnostic and should be interpreted in the context of other clinical and laboratory findings, such as those associated with thrombotic thrombocytopenic purpura [38]. The elevated D-dimer likely reflects the increased fibrin turnover associated with microthrombi formation in PTTM. Similarly, a prolonged prothrombin time can indicate a consumption coagulopathy, a hallmark of PTTM. Anemia and thrombocytopenia are likely secondary to microvascular thrombosis and platelet consumption in the setting of DIC. The presence of these laboratory abnormalities together with respiratory deterioration suggests PTTM [25,57].

PTTM should also be considered in rapidly dyspneic cancer patients with the presence of PAH on echocardiography without any apparent cause, and with the absence of pulmonary arterial thrombus on chest computed tomography (CT) [57]. Use of pulmonary aspiration cytopathology for antemortem diagnosis has been reported in a few cases [51,58]. For imaging, the use of 18F-fluorodeoxyglucose positron emission tomography/CT has been reported in multiple studies [24,59,60]. Case reports by Tashima et al. [59] and Kamada et al. [60] demonstrated multiple foci with abnormal FDG uptake in both lungs affected by PTTM.

Chronic pulmonary thromboembolism (CTEPH) is a distinct clinical entity that can be challenging to differentiate from PTTM. While both conditions can present with respiratory symptoms, their clinical manifestations and diagnostic approaches differ. In contrast to the acute presentation of PTTM, CTEPH often has a more insidious onset with less prominent respiratory symptoms. Cough, a common feature of acute PTTM, is less frequently observed in CTEPH. CT findings can also be helpful in differentiating the two conditions. In PTTM cases, ground-glass opacities, nodules, mediastinal and hilar lymphadenopathy, and septal thickening are often revealed. In contrast, CTEPH cases may demonstrate mosaicism, wedge-shaped infarcts, organized and calcified thrombus, and enlarged bronchial artery [57]. Additionally, laboratory findings in CTEPH are typically nonspecific and may not reveal the characteristic thrombocytopenia and DIC seen in PTTM [25,61]. Table 3 summarizes the clinical presentation and diagnosis of PTTM.

Feature	Description
Common symptoms	Cough, sputum production, shortness of breath, inability to lie flat, chest tightness, chest pain, hemoptysis, fever, malaise, and wasting
Diagnostic approach	Combination of medical history, physical examination, imaging (echocardiography, CT), and laboratory tests
Importance of early diagnosis	A delay in diagnosis worsens prognosis, increases risk of thromboembolic events, and negatively impacts quality of life
Diagnostic challenges	High rate of postmortem diagnosis, difficulty in differentiating from other pulmonary conditions, and PAH on echocardiography and CT without any apparent cause
Clinical presentation	PAH, right ventricular failure, abnormal laboratory findings (increase in D-dimer and prothrombin time, anemia, thrombocytopenia, DIC), and schistocytes in peripheral blood smear
Diagnostic tools	Pulmonary aspiration cytopathology, FDG-PET/CT. Chest CT may not show typical pulmonary embolism. FDG-PET/CT can reveal multiple lung nodules

Table 3: Summary of the clinical presentation and diagnosis of pulmonary tumor thrombotic microangiopathy

Source: [24,25,38,51,57-60]

CT, computed tomography; FDG-PET, 18F-fluorodeoxyglucose positron emission tomography; PAH, pulmonary arterial hypertension

Treatment and prognosis of pulmonary tumor thrombotic microangiopathy

The choice of medication depends on the individual patient and the severity of their condition. Apart from oxygen therapy, the medications used to treat PTTM include those for advanced PAH, such as sildenafil, tadalafil, ambrisentan, bosentan, and epoprostenol [62]. Diuretics such as furosemide and spironolactone help reduce fluid overload, while corticosteroids such as dexamethasone and prednisone have anti-inflammatory effects. Given that PTTM presents with consumptive coagulopathy, anticoagulants should be used with caution. In such cases, low-molecular-weight heparin may be the optimal strategy [63]. In pulmonary embolism, the pathology is primarily caused by the activation of the blood coagulation cascade, but in PTTM, fibroproliferative changes in the vascular lumen arising from TF release are the prominent causes. Therefore, while anticoagulant therapy may be effective for pulmonary embolism, it cannot improve PTTM. In the case of right heart failure, intravenous diuresis, inotropic support, and pulmonary vasodilator therapy should be considered [54]. A multidisciplinary approach involving pulmonologists, oncologists, and other specialists is essential for the optimal management of PTTM patients. A patient-centered approach, which includes timely supportive care and symptom management, can improve quality of life and alleviate symptoms.

At present, PTTM management lacks a consistent, evidence-based approach due to the condition’s rarity and rapid progression, which frequently leads to late diagnosis and intervention. Almost all patients with PTTM die within a week of the dyspnea onset due to progressive PAH, subacute right heart failure, or sudden death [53,64]. The rarity of PTTM poses significant challenges to research, including small sample sizes and difficulty in recruitment for clinical trials. While anti-inflammatory therapy with corticosteroids has been frequently utilized as a potential treatment strategy for PTTM, its efficacy remains uncertain [53,65-67]. A case report by Miyazaki et al. demonstrated a temporary improvement in lung function and right ventricular pressure overload following corticosteroid administration [53]. However, the patient ultimately succumbed to respiratory failure, highlighting the limitations of current therapeutic approaches and the need for further research to identify effective interventions for this challenging condition. Other studies similarly reported the ineffectiveness of anti-coagulants and corticosteroids [65-67].

Clinical reports suggest that bevacizumab may be a valuable therapeutic option for patients with PTTM, especially when used in conjunction with other therapies. Higo et al. presented a case study of a colorectal cancer patient exhibiting PTTM who underwent a combination therapy involving imatinib, a PDGF receptor antagonist, bevacizumab, a VEGF receptor inhibitor, and the chemotherapeutic agents S-1 and cisplatin [68]. Following this treatment regimen, the patient exhibited a significant improvement in symptoms without experiencing a deterioration of PAH. However, 12 months post-treatment, the patient succumbed to respiratory failure secondary to an influenza infection. Despite this outcome, the authors posit that the molecular-targeted drugs employed in the therapy were efficacious in managing PTTM based on the patient’s clinical trajectory [68]. Kotake et al. reported a significant improvement of PTTM with lung adenocarcinoma in terms of PAH, respiratory symptoms, and other outcomes after bevacizumab treatment combined with paclitaxel and carboplatin [69]. Taniguchi et al. reported a similar improvement in uterine cancer-induced PTTM after successful treatment with platinum-based chemotherapy and bevacizumab [70]. These case studies suggest that bevacizumab, in combination with other therapies, may be a promising treatment option for PTTM, especially when used in conjunction with targeted therapies. Bevacizumab therapy can be associated with adverse effects. The most common side effect is hypertension, which requires regular blood pressure monitoring and effective management with antihypertensive medications. Proteinuria, thromboembolism, impaired wound healing, and bleeding are other clinically encountered side effects [71]. In more severe cases, a minority of patients may develop thrombotic microangiopathy (TMA). Bevacizumab-associated TMA, along with other drug-induced TMAs, is currently an indication for drug discontinuation due to poor prognosis, including acute kidney injury often requiring dialysis and progression to chronic kidney disease. Most cases, however, improve after discontinuation of bevacizumab [72].

Imatinib has demonstrated promising results in addressing complications associated with PTTM, as evidenced by several case studies. The efficacy of imatinib in treating a patient with PAH associated with PTTM has been demonstrated by the case study of Ogawa et al. [73]. Following imatinib therapy, the patient experienced a dramatic reduction in PAH, enabling successful weaning from percutaneous cardiopulmonary support within a 20-day timeframe. Based on these findings, the authors suggested that imatinib may be a viable therapeutic option for alleviating PAH arising from PTTM [73]. Kimura et al. [74] reported a case of a breast cancer patient with PTTM who experienced a dramatic improvement with bevacizumab therapy. The patient received paclitaxel and bevacizumab for one year, successfully controlling the condition and extending their survival to one year and eight months. This case highlighted the potential efficacy of bevacizumab in managing PTTM associated with breast cancer [74]. Another case study reported that bevacizumab combined with pemetrexed significantly improved lung adenocarcinoma-induced PTTM respiratory dysfunction [52]. Yoshikawa et al. also reported a case of PTTM associated with metastatic breast cancer, which exhibited a significant improvement of respiratory dysfunction and PAH after imatinib was administered [75]. Similarly, imatinib dramatically alleviated the PTTM induced by gastric cancer in another case report by Kubota et al [76]. These findings underscore the potential of imatinib as a targeted therapy for PTTM. Yet still, imatinib can cause a range of cutaneous side effects, along with fever and diarrhea. A maculopapular rash is the most common. For many patients experiencing intolerable side effects, temporarily reducing the dose can help resolve the issue [77]. Furthermore, while both bevacizumab and imatinib are approved medications, access can be challenging due to factors such as cost, insurance coverage, and availability. Similar to bevacizumab, imatinib can also result in drug-mediated TMA, as reported in two cases [78]. Therefore, the administration of bevacizumab and imatinib should be considered carefully, taking into account the potential for drug-mediated TMA. Table 4 summarizes the referred studies regarding the treatment and prognosis of adenocarcinoma-induced PTTM.

Study author(s)	Type of study	Patient cancer type	Treatment	Outcome
Lu et al. [52]	Case report	Lung adenocarcinoma	Bevacizumab, pemetrexed	Successful improvement in chest CT findings, respiratory symptoms, DIC. On the second day, dyspnea improved, and The patient could complete walking exercises. Cough was gradually relieved, without any further hemoptysis, together with significantly improved fatigue, sleep, food intake, and mental and physical status
Miyazaki et al. [53]	Case report	Gastric cancer	Corticosteroids	Temporary improvement in lung function and right ventricular pressure, but eventual death from respiratory failure
Higo et al. [68]	Case report	Colorectal cancer	Imatinib, bevacizumab, s-1, cisplatin	Significant improvement in symptoms without deterioration of PAH, but eventual death from respiratory failure
Kotake et al. [69]	Case report	Lung adenocarcinoma	Carboplatin, paclitaxel, and bevacizumab	Successful improvement in PAH, respiratory symptoms, and other outcomes. On day 10, oxygen saturation rate was improved to 95%, and she was discharged after recovery was confirmed
Taniguchi et al. [70]	Case report	Uterine cancer	Carboplatin, paclitaxel, and bevacizumab	Patient’s respiratory status and radiological findings improved concomitantly with a reduction in the size of the tumor. The patient recovered well from respiratory failure and her condition has improved, even six months after the end of treatment
Ogawa et al. [73]	Case report	Gastric and duodenal carcinoma	Imatinib	Dramatic amelioration of a PAH   patient was able to be weaned from percutaneous cardiopulmonary support within 20 days of treatment
Kimura et al. [74]	Case report	Stage IV left-sided breast cancer	Paclitaxel and bevacizumab for breast cancer and concurrent treatment for PAH and DIC	Successful control of the condition with paclitaxel and bevacizumab for a year. The patient survived for 1 year and 8 months
Yoshikawa et al. [75]	Case report	Metastatic breast cancer	Imatinib	Patient exhibited significant improvement of respiratory dysfunction and PAH
Kubota et al. [76]	Case report	Gastric cancer, signet-ring cell carcinoma	Imatinib	Significant decrease in mean pulmonary arterial pressure five days after imatinib administration. The patient was discharged and lived without symptoms of PAH until her death due to systemic metastasis of carcinoma

Table 4: Summary of referred studies regarding the treatment and prognosis of PTTM

DIC, disseminated intravascular coagulation; PAH, pulmonary arterial hypertension; PTTM, pulmonary tumor thrombotic microangiopathy

These case studies suggest that targeted therapies, such as bevacizumab and imatinib, may offer promising therapeutic options for patients with PTTM. While further research is needed to establish definitive treatment guidelines, these studies provide valuable insights into the potential benefits of these agents in managing PTTM-related complications. It’s important to note that the referred studies are case reports. While valuable for generating hypotheses and describing rare occurrences, case reports have inherent limitations that should be considered. These limitations include limited generalizability, lack of a control group, potential for bias, limited statistical power, and a retrospective nature. Further research, such as larger observational studies or randomized controlled trials, is often needed to confirm the findings and draw more definitive conclusions.

Future research should focus on identifying additional biomarkers that can predict patient response to these therapies and developing novel therapeutic strategies that target the underlying pathophysiological mechanisms of PTTM. These mechanisms may include the activation of coagulation cascade and release of inflammatory mediators, fibrocellular subintimal proliferation, and smooth muscle cell colonization [28]. Several potential biomarkers have been associated with PTTM, including VEGF, PDGF, osteopontin, and TF [35]. These biomarkers are involved in pathways that contribute to the pathophysiology of PTTM, including angiogenesis, coagulation, and cellular proliferation. Further research is needed to validate their utility in clinical practice and to explore their potential in early diagnosis and targeted therapy for PTTM.

Conclusions

In conclusion, the association between adenocarcinoma and PTTM presents a significant clinical challenge. Current treatment strategies for PTTM in adenocarcinoma patients primarily focus on managing the underlying malignancy and addressing thrombotic complications. Anti-angiogenic therapy bevacizumab and a PDGF receptor antagonist imatinib have shown promising results in some cases.

Future research should focus on the early detection of PTTM in adenocarcinoma patients, understanding the molecular mechanisms underlying the association between these two diseases, and developing innovative therapeutic approaches that target the aforementioned specific pathophysiological processes involved. By advancing our understanding of PTTM in adenocarcinoma, we can improve patient outcomes and ultimately save lives.

References

1. Spiro SG, Gould MK, Colice GL: Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007, 132:149S-60S. 10.1378/chest.07-1358
2. Thapa B, Mahendraker N, Ramphul K: Paraneoplastic syndromes. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024.
3. Baijens LW, Manni JJ: Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol. 2006, 263:32-6. 10.1007/s00405-005-0942-1
4. Chan AM, Baehring JM: Paraneoplastic neurological syndromes: a single institution 10-year case series. J Neurooncol. 2019, 141:431-9. 10.1007/s11060-018-03053-3
5. Grisold W, Giometto B, Vitaliani R, Oberndorfer S: Current approaches to the treatment of paraneoplastic encephalitis. Ther Adv Neurol Disord. 2011, 4:237-48. 10.1177/1756285611405395
6. van Sonderen A, Wirtz PW, Verschuuren JJ, Titulaer MJ: Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurol. 2013, 15:224-39. 10.1007/s11940-012-0213-6
7. Barbosa SL, Rodien P, Leboulleux S, et al.: Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid. 2005, 15:618-23. 10.1089/thy.2005.15.618
8. Peri A, Grohé C, Berardi R, Runkle I: SIADH: differential diagnosis and clinical management. Endocrine. 2017, 55:311-9. 10.1007/s12020-016-0936-3
9. Bodnar TW, Acevedo MJ, Pietropaolo M: Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014, 99:713-22. 10.1210/jc.2013-3382
10. Gade AK, Olariu E, Douthit NT: Carcinoid syndrome: a review. Cureus. 2020, 12:e7186. 10.7759/cureus.7186
11. Mulatero P, Rabbia F, Veglio F: Paraneoplastic hyperaldosteronism associated with non-Hodgkin’s lymphoma. N Engl J Med. 2001, 344:1558-9. 10.1056/NEJM200105173442017
12. Khan F, Kleppel H, Meara A: Paraneoplastic musculoskeletal syndromes. Rheum Dis Clin North Am. 2020, 46:577-86. 10.1016/j.rdc.2020.04.002
13. Azar L, Khasnis A: Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol. 2013, 25:44-9. 10.1097/BOR.0b013e328359e780
14. Muller S, Hider S, Helliwell T, Partington R, Mallen C: The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome. Reumatismo. 2018, 70:23-34. 10.4081/reumatismo.2018.1031
15. Da Silva JL, Lacombe C, Bruneval P, et al.: Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood. 1990, 75:577-82.
16. Suzuki M, Takamizawa S, Nomaguchi K, Suzu S, Yamada M, Igarashi T, Sato I: Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol. 2001, 113:49-51. 10.1046/j.1365-2141.2001.02682.x
17. Kew MC, Fisher JW: Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer. 1986, 58:2485-8. 10.1002/1097-0142(19861201)58:11<2485::aid-cncr2820581122>3.0.co;2-n
18. Dourmishev LA, Draganov PV: Paraneoplastic dermatological manifestation of gastrointestinal malignancies. World J Gastroenterol. 2009, 15:4372-9. 10.3748/wjg.15.4372
19. Wick MR, Patterson JW: Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019, 36:211-28. 10.1053/j.semdp.2019.01.001
20. Dhanapriya J, Dineshkumar T, Sakthirajan R, Surendar D, Gopalakrishnan N, Balasubramaniyan T: Paraneoplastic glomerulopathies associated with hematologic malignancies. Saudi J Kidney Dis Transpl. 2018, 29:452-5. 10.4103/1319-2442.229260
21. Christiansen CF, Onega T, Sværke C, Körmendiné Farkas D, Jespersen B, Baron JA, Sørensen HT: Risk and prognosis of cancer in patients with nephrotic syndrome. Am J Med. 2014, 127:871-7.e1. 10.1016/j.amjmed.2014.05.002
22. Guddati AK, Marak CP: Pulmonary lymphangitic carcinomatosis due to renal cell carcinoma. Case Rep Oncol. 2012, 5:246-52. 10.1159/000339126
23. Leick M, Chen YB: Paraneoplastic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2022, 205:e55. 10.1164/rccm.202202-0260IM
24. Uruga H, Fujii T, Kurosaki A, et al.: Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med. 2013, 52:1317-23. 10.2169/internalmedicine.52.9472
25. Godbole RH, Saggar R, Kamangar N: Pulmonary tumor thrombotic microangiopathy: a systematic review. Pulm Circ. 2019, 9:2045894019851000. 10.1177/2045894019851000
26. von Herbay A, Illes A, Waldherr R, Otto HF: Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 1990, 66:587-92. 10.1002/1097-0142(19900801)66:3<587::aid-cncr2820660330>3.0.co;2-j
27. Connected Papers | Find and explore academic papers [Internet]. (2024). Accessed: March 25, 2024: http://www.connectedpapers.com.
28. Mendeley – Reference Management Software & Researcher Network [Internet]. (2024). Accessed: March 25, 2024: http://www.mendeley.com.
29. Chan CK, Hutcheon MA, Hyland RH, Smith GJ, Patterson BJ, Matthay RA: Pulmonary tumor embolism: a critical review of clinical, imaging, and hemodynamic features. J Thorac Imaging. 1987, 2:4-14.
30. Roberts KE, Hamele-Bena D, Saqi A, Stein CA, Cole RP: Pulmonary tumor embolism: a review of the literature. Am J Med. 2003, 115:228-32. 10.1016/s0002-9343(03)00305-x
31. McCabe BE, Veselis CA, Goykhman I, Hochhold J, Eisenberg D, Son H: Beyond pulmonary embolism; nonthrombotic pulmonary embolism as diagnostic challenges. Curr Probl Diagn Radiol. 2019, 48:387-92. 10.1067/j.cpradiol.2018.07.007
32. Pinckard JK, Wick MR: Tumor-related thrombotic pulmonary microangiopathy: review of pathologic findings and pathophysiologic mechanisms. Ann Diagn Pathol. 2000, 4:154-7. 10.1016/s1092-9134(00)90038-8
33. Friedman SH, Harley RA, Williams J, et al.: Pathologic differences between systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. J Scleroderma Relat Disord. 2024, 23971983241296721. 10.1177/23971983241296721
34. Skalli O, Pelte MF, Peclet MC, et al.: Alpha-smooth muscle actin, a differentiation marker of smooth muscle cells, is present in microfilamentous bundles of pericytes. J Histochem Cytochem. 1989, 37:315-21. 10.1177/37.3.2918221
35. Kumar N, Price LC, Montero MA, Dimopoulos K, Wells AU, Wort SJ: Pulmonary tumour thrombotic microangiopathy: unclassifiable pulmonary hypertension?. Eur Respir J. 2015, 46:1214-7. 10.1183/13993003.00052-2015
36. Kuwabara H, Yoshida S, Takasu T, Yuki M, Goto I, Hanafusa T, Shibayama Y: Pulmonary tumor thrombotic microangiopathy caused by gastric cancer. Ann Thorac Med. 2012, 7:168-9. 10.4103/1817-1737.98853
37. Sato Y, Marutsuka K, Asada Y, Yamada M, Setoguchi T, Sumiyoshi A: Pulmonary tumor thrombotic microangiopathy. Pathol Int. 1995, 45:436-40. 10.1111/j.1440-1827.1995.tb03481.x
38. Okubo Y, Wakayama M, Kitahara K, et al.: Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: morphometric and immunohistochemical analysis of six autopsy cases. Diagn Pathol. 2011, 6:27. 10.1186/1746-1596-6-27
39. Wakabayashi Y, Iwaya M, Akita M, Takeuchi W, Yamazaki K, Iijima A: Pulmonary tumor thrombotic microangiopathy caused by urothelial carcinoma expressing vascular endothelial growth factor, platelet-derived growth factor, and osteopontin. Intern Med. 2016, 55:651-6. 10.2169/internalmedicine.55.5758
40. Muramatsu S, Fujiwara M, Kazunari K, Watanabe M, Watanabe N: Pulmonary tumor thrombotic microangiopathy with versican expression in a patient with advanced gastric cancer: a case report of a rare autopsy. Cureus. 2024, 16:e65690. 10.7759/cureus.65690
41. Chang YT, Chan CK, Eriksson I, et al.: Versican accumulates in vascular lesions in pulmonary arterial hypertension. Pulm Circ. 2016, 6:347-59. 10.1086/686994
42. Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, He J: TGF-β signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024, 9:61. 10.1038/s41392-024-01764-w
43. Chang MY, Tanino Y, Vidova V, et al.: A rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease. Matrix Biol. 2014, 34:1-12. 10.1016/j.matbio.2014.01.011
44. Kirchhofer D, Tschopp TB, Hadváry P, Baumgartner HR: Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest. 1994, 93:2073-83. 10.1172/JCI117202
45. Lee NK, Kim S, Kim HS, et al.: Spectrum of mucin-producing neoplastic conditions of the abdomen and pelvis: cross-sectional imaging evaluation. World J Gastroenterol. 2011, 17:4757-71. 10.3748/wjg.v17.i43.4757
46. Shao B, Wahrenbrock MG, Yao L, et al.: Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 2011, 118:4015-23. 10.1182/blood-2011-07-368514
47. Geddings JE, Mackman N: Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013, 122:1873-80. 10.1182/blood-2013-04-460139
48. Obermeier HL, Riedl J, Ay C, et al.: The role of ADAMTS-13 and von Willebrand factor in cancer patients: results from the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost. 2019, 3:503-14. 10.1002/rth2.12197
49. Pépin M, Kleinjan A, Hajage D, et al.: ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016, 14:306-15. 10.1111/jth.13205
50. Cesari M, Pahor M, Incalzi RA: Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010, 28:e72-91. 10.1111/j.1755-5922.2010.00171.x
51. Unno K, Ohtani H, Sakamoto A, et al.: Pulmonary tumor thrombotic microangiopathy caused by metastatic ovarian cancer: an antemortem diagnosis with pulmonary aspiration cytopathology. Intern Med. 2023, 62:3649-55. 10.2169/internalmedicine.1641-23
52. Lu L, Wang Z, Li H, Li X, Ma S, Wang L, Yang B: Bevacizumab combined with pemetrexed successfully treated lung adenocarcinoma complicated with pulmonary tumor thrombotic microangiopathy: a case report and literature review. Ann Palliat Med. 2021, 10:767-77. 10.21037/apm-20-2220
53. Miyazaki S, Ikeda T, Ito G, Inoue M, Nara K, Nishinaga Y, Hasegawa Y: Pulmonary tumor thrombotic microangiopathy successfully treated with corticosteroids: a case report. J Med Case Rep. 2017, 11:356. 10.1186/s13256-017-1524-8
54. Suffredini DA, Lee JM, Peer CJ, Pratt D, Kleiner DE, Elinoff JM, Solomon MA: Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab. BMC Pulm Med. 2018, 18:112. 10.1186/s12890-018-0681-x
55. Jiménez-Labaig P, Fernández Solé S, Gómez Varela S, García Calvo J, Carrera Revilla S, Muñoz Llarena A: A rare, life-threatening debut of pancreatic adenocarcinoma: pulmonary tumor thrombotic microangiopathy. Curr Probl Cancer Case Rep. 2023, 10:100238. 10.1016/j.cpccr.2023.100238
56. Bak M, Kim M, Lee B, et al.: Clinical course of suspected diagnosis of pulmonary tumor thrombotic microangiopathy: a 10-year experience of rapid progressive right ventricular failure syndrome in advanced cancer patients. Korean Circ J. 2023, 53:170-84. 10.4070/kcj.2022.0252
57. Kim KA, Jung MH: Pulmonary tumor thrombotic microangiopathy: an under-recognized potentially fatal cause of pulmonary hypertension. Korean Circ J. 2023, 53:185-8. 10.4070/kcj.2023.0019
58. Onoda H, Imamura T, Inao K, Kinugawa K: How to diagnose and treat pulmonary tumor thrombotic microangiopathy. Int Heart J. 2020, 61:409-12. 10.1536/ihj.19-549
59. Tashima Y, Abe K, Matsuo Y, et al.: Pulmonary tumor thrombotic microangiopathy: FDG-PET/CT findings. Clin Nucl Med. 2009, 34:175-7. 10.1097/RLU.0b013e3181966f5c
60. Kamada H, Ota H, Terui Y, Sugimura K, Fukui S, Shimokawa H, Takase K: Three cases of pulmonary tumor thrombotic microangiopathy (PTTM): challenge in antemortem diagnosis using lung perfusion blood volume images by dual-energy computed tomography. Eur J Radiol Open. 2020, 7:100212. 10.1016/j.ejro.2020.01.001
61. Jung MH, Jung HO, Kwon SJ, Chang S: Clinical presentations and multimodal imaging diagnosis in chronic thromboembolic pulmonary hypertension. J Clin Med. 2022, 11:6678. 10.3390/jcm11226678
62. Tran K, Coyle K, Jabr MF, et al.: Discussion. Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet]. Tran K, Coyle K, Jabr MF, et al. (ed): Canadian Agency for Drugs and Technologies in Health, Ottawa; 2015.
63. Ramakrishnan P, Dahiya G, Lindstrom M, Thenappan T: Pulmonary tumor thrombotic microangiopathy: exploration into current diagnostic aids and therapeutics. Pulm Circ. 2023, 13:e12278. 10.1002/pul2.12278
64. Sato N, Tasaki T, Noguchi H, Irie K, Nakayama T: The pathological challenge of establishing a precise diagnosis for pulmonary tumour thrombotic microangiopathy: identification of new diagnostic criteria. Histopathology. 2019, 74:892-901. 10.1111/his.13813
65. Chen CK: Pulmonary tumor thrombotic microangiopathy: case report and literature review. J Acute Med. 2018, 8:127-31. 10.6705/j.jacme.201809_8(3).0006
66. McAnearney S, Drain M: A case of pulmonary tumour thrombotic microangiopathy. Respir Med Case Rep. 2015, 16:7-10. 10.1016/j.rmcr.2015.04.006
67. Gainza E, Fernández S, Martínez D, et al.: Pulmonary tumor thrombotic microangiopathy: report of 3 cases and review of the literature. Medicine (Baltimore). 2014, 93:359-63. 10.1097/MD.0000000000000219
68. Higo K, Kubota K, Takeda A, Higashi M, Ohishi M: Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med. 2014, 53:2595-9. 10.2169/internalmedicine.53.2379
69. Kotake T, Adachi Y, Honde K, et al.: Early diagnosis and bevacizumab combined with chemotherapy improved pulmonary tumor thrombotic microangiopathy with lung adenocarcinoma: a case report. Curr Probl Cancer Case Rep. 2022, 7:100173. 10.1016/j.cpccr.2022.100173
70. Taniguchi J, Nakashima K, Matsuura T, et al.: Long-term survival of a patient with uterine cancer-induced pulmonary tumor thrombotic microangiopathy following treatment with platinum-based chemotherapy and bevacizumab: a case report. Respir Med Case Rep. 2021, 33:101447. 10.1016/j.rmcr.2021.101447
71. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A: Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009, 66:999-1013. 10.2146/ajhp080455
72. Padilha WS, Cesar BN, Pacheco ST, De Sousa AA, Ledesma FL, Malheiros DM, Teixeira MC: Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case report. Am J Case Rep. 2023, 24:e940906. 10.12659/AJCR.940906
73. Ogawa A, Yamadori I, Matsubara O, Matsubara H: Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med. 2013, 52:1927-30. 10.2169/internalmedicine.52.0718
74. Kimura A, Yamada A, Oshi M, et al.: Dramatic improvement of pulmonary tumor thrombotic microangiopathy in a breast cancer patient treated with bevacizumab. World J Oncol. 2023, 14:575-9. 10.14740/wjon1691
75. Yoshikawa S, Hara T, Suzuki M, Fujioka M, Taniguchi Y, Hirata KI: Imatinib dramatically improved pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy (PTTM) associated with metastatic breast cancer. Int Heart J. 2020, 61:624-8. 10.1536/ihj.19-556
76. Kubota K, Shinozaki T, Imai Y, Kario K: Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer. BMJ Case Rep. 2017, 2017:bcr2017221032. 10.1136/bcr-2017-221032
77. Uzer E, Unal A, Köker MY, Doğan SA: The side effects of imatinib. Turk J Haematol. 2013, 30:341. 10.4274/Tjh-2011.0018
78. Ojeda-Uribe M, Merieau S, Guillon M, et al.: Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate. J Oncol Pharm Pract. 2016, 22:361-70. 10.1177/1078155214568580